Human Cell Culture Volume II

por Johnston, P G
Publicado 2000

The effect of dose and interval between 5-fluorouracil and leucovorin on the formation of thymidylate synthase ternary complex in human cancer cells.

por Drake, J. C., Voeller, D. M., Allegra, C. J., Johnston, P. G.
Publicado 1995

Determinants of trimetrexate lethality in human colon cancer cells.

por Grem, J. L., Voeller, D. M., Geoffroy, F., Horak, E., Johnston, P. G., Allegra, C. J.
Publicado 1994

Investigation of systemic folate status, impact of alcohol intake and levels of DNA damage in mononuclear cells of breast cancer patients

por Hussien, M M I, McNulty, H, Armstrong, N, Johnston, P G, Spence, R A J, Barnett, Y
Publicado 2005

Increased expression of the RIα subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer

por McDaid, H M, Cairns, M T, Atkinson, R J, McAleer, S, Harkin, D P, Gilmore, P, Johnston, P G
Publicado 1999

Increased thymidylate synthase protein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells.

por Pestalozzi, B. C., McGinn, C. J., Kinsella, T. J., Drake, J. C., Glennon, M. C., Allegra, C. J., Johnston, P. G.
Publicado 1995

Apoptosome-dependent caspase activation proteins as prognostic markers in Stage II and III colorectal cancer

por Hector, S, Conlon, S, Schmid, J, Dicker, P, Cummins, R J, Concannon, C G, Johnston, P G, Kay, E W, Prehn, J H M
Publicado 2012

Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients

por Paradiso, A, Simone, G, Petroni, S, Leone, B, Vallejo, C, Lacava, J, Romero, A, Machiavelli, M, Lena, M De, Allegra, C J, Johnston, P G
Publicado 2000

Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma

por Wong, N A C S, Brett, L, Stewart, M, Leitch, A, Longley, D B, Dunlop, M G, Johnston, P G, Lessells, A M, Jodrell, D I
Publicado 2001

The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue

por Oladipo, O, Conlon, S, O'Grady, A, Purcell, C, Wilson, C, Maxwell, P J, Johnston, P G, Stevenson, M, Kay, E W, Wilson, R H, Waugh, D J J
Publicado 2011

SAHA overcomes FLIP-mediated inhibition of SMAC mimetic-induced apoptosis in mesothelioma

por Crawford, N, Stasik, I, Holohan, C, Majkut, J, McGrath, M, Johnston, P G, Chessari, G, Ward, G A, Waugh, D J, Fennell, D A, Longley, D B
Publicado 2013

Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer

por Turkington, R C, Longley, D B, Allen, W L, Stevenson, L, McLaughlin, K, Dunne, P D, Blayney, J K, Salto-Tellez, M, Van Schaeybroeck, S, Johnston, P G
Publicado 2014

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer

por Wilson, C, Scullin, P, Worthington, J, Seaton, A, Maxwell, P, O'Rourke, D, Johnston, P G, McKeown, S R, Wilson, R H, O'Sullivan, J M, Waugh, D J J
Publicado 2008

The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study

por Gormley, J A, Hegarty, S M, O'Grady, A, Stevenson, M R, Burden, R E, Barrett, H L, Scott, C J, Johnston, J A, Wilson, R H, Kay, E W, Johnston, P G, Olwill, S A
Publicado 2011

Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity

por Schmid, D, Jarvis, G E, Fay, F, Small, D M, Greene, M K, Majkut, J, Spence, S, McLaughlin, K M, McCloskey, K D, Johnston, P G, Kissenpfennig, A, Longley, D B, Scott, C J
Publicado 2014

Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer

por Riley, J S, Hutchinson, R, McArt, D G, Crawford, N, Holohan, C, Paul, I, Van Schaeybroeck, S, Salto-Tellez, M, Johnston, P G, Fennell, D A, Gately, K, O'Byrne, K, Cummins, R, Kay, E, Hamilton, P, Stasik, I, Longley, D B
Publicado 2013

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial

por Cassidy, J, Douillard, J-Y, Twelves, C, McKendrick, J J, Scheithauer, W, Bustová, I, Johnston, P G, Lesniewski-Kmak, K, Jelic, S, Fountzilas, G, Coxon, F, Díaz-Rubio, E, Maughan, T S, Malzyner, A, Bertetto, O, Beham, A, Figer, A, Dufour, P, Patel, K K, Cowell, W, Garrison, L P
Publicado 2006